Clinical trials: Multiple Myeloma or Plasmacytoma
Multiple Myeloma
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
This Phase 1 study of oral CX-4945 is designed to test the safety, tolerability, and highest safe dose level of this CK2 inhibitor in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT01199718
- Testing
- CX-4945
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Cylene Pharmaceuticals
Multiple Myeloma, Plasma Cell Leukemia
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
This is a 2-phase study during which patients with relapsed or refractory multiple myeloma (MM) or plasma cell leukemia (PCL), who have already received at least two previous treatments, will receive investigational study drug…
- Trial name
- NCT00821249
- Testing
- ARRY-520, KSP(Eg5) inhibitor; intravenous, Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous, Dexamethasone, steroid; oral
- Where
- 5 sites in United States
- Volunteers
- 55 people
- Sponsor
- Pfizer
Multiple Myeloma and Other Plasma Cell Neoplasms
Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
This study is a 2-part study with a dose-escalation part and a dose-expansion part. The aim of the dose-escalation part is to determine the maximum tolerated dose (MTD) and/or establish the recommended Phase 2 dose (RP2D) in the…
- Trial name
- NCT07529782
- Testing
- HDP-101
- Where
- 5 sites in China
- Volunteers
- 15 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Waldenstrom Macroglobulinemia, Multiple Myeloma
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic…
- Conditions
- Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- CLOVER-WaM (NCT02952508)
- Testing
- Iopofosine I 131 single dose, Iopofosine I 131 multiple dose, Iopofosine I 131 fractionated dose
- Where
- 52 sites in United States, Australia and 9 more
- Volunteers
- 120 people
- Sponsor
- Cellectar Biosciences, Inc.
Multiple Myeloma
Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting
This trial will evaluate the efficacy and safety of combination of pomalidomide (POM) and low-dose dexamethasone (LD-Dex) (Cohort A) or the combination of pomalidomide (POM) , daratumumab (DARA) and low-dose dexamethasone…
- Trial name
- POM MM 014 (NCT01946477)
- Testing
- Pomalidomide, Dexamethasone, Daratumumab
- Where
- 49 sites in United States, Canada and 2 more
- Volunteers
- 186 people
- Sponsor
- Celgene
Multiple Myeloma
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to assess the effects of administration of daratumumab when combined with VELCADE (bortezomib) and dexamethasone compared with bortezomib and dexamethasone alone, for participants with relapsed or…
- Trial name
- NCT02136134
- Testing
- Daratumumab, VELCADE (Bortezomib), Dexamethasone
- Where
- 105 sites in United States, Australia and 13 more
- Volunteers
- 498 people
- Sponsor
- Janssen Research & Development, LLC